178 related articles for article (PubMed ID: 17388711)
1. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.
Caroff SN; Walker P; Campbell C; Lorry A; Petro C; Lynch K; Gallop R
J Clin Psychiatry; 2007 Mar; 68(3):410-5. PubMed ID: 17388711
[TBL] [Abstract][Full Text] [Related]
2. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study.
Libov I; Miodownik C; Bersudsky Y; Dwolatzky T; Lerner V
J Clin Psychiatry; 2007 Jul; 68(7):1031-7. PubMed ID: 17685739
[TBL] [Abstract][Full Text] [Related]
4. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
[TBL] [Abstract][Full Text] [Related]
5. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
[TBL] [Abstract][Full Text] [Related]
7. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Pappa S; Tsouli S; Apostolou G; Mavreas V; Konitsiotis S
Clin Neuropharmacol; 2010; 33(6):271-5. PubMed ID: 21121175
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
Bergman J; Dwolatzky T; Brettholz I; Lerner V
J Clin Psychiatry; 2005 Jan; 66(1):107-10. PubMed ID: 15669896
[TBL] [Abstract][Full Text] [Related]
9. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
10. Treatment of tardive dyskinesia with donepezil: a pilot study.
Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
[TBL] [Abstract][Full Text] [Related]
11. Is melatonin treatment effective for tardive dyskinesia?
Shamir E; Barak Y; Plopsky I; Zisapel N; Elizur A; Weizman A
J Clin Psychiatry; 2000 Aug; 61(8):556-8. PubMed ID: 10982197
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic medication for neuroleptic-induced tardive dyskinesia.
Tammenmaa IA; McGrath JJ; Sailas E; Soares-Weiser K
Cochrane Database Syst Rev; 2002; (3):CD000207. PubMed ID: 12137608
[TBL] [Abstract][Full Text] [Related]
13. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
[TBL] [Abstract][Full Text] [Related]
14. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia.
Suddath RL; Straw GM; Freed WJ; Bigelow LB; Kirch DG; Wyatt RJ
Pharmacol Biochem Behav; 1991 Jul; 39(3):743-5. PubMed ID: 1686106
[TBL] [Abstract][Full Text] [Related]
15. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Lerner V; Miodownik C; Kaptsan A; Cohen H; Matar M; Loewenthal U; Kotler M
Am J Psychiatry; 2001 Sep; 158(9):1511-4. PubMed ID: 11532741
[TBL] [Abstract][Full Text] [Related]
16. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
[TBL] [Abstract][Full Text] [Related]
17. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
[TBL] [Abstract][Full Text] [Related]
18. Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo.
Sommer BR; Cohen BM; Satlin A; Cole JO; Jandorf L; Dorsey F
J Geriatr Psychiatry Neurol; 1994; 7(4):234-7. PubMed ID: 7826493
[TBL] [Abstract][Full Text] [Related]
19. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
20. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
